The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Analysis of the impact of eliminating bolus 5-fluorouracil in metastatic colorectal cancer.
 
Chengwei Peng
No Relationships to Disclose
 
Saad Saffo
No Relationships to Disclose
 
Michael Shusterman
No Relationships to Disclose
 
Daniel Jacob Becker
No Relationships to Disclose
 
Jordan Berlin
Consulting or Advisory Role - Bayer Health; BioSapien; insmed; ipsen; Merck KGaA; Mirati Therapeutics; Oxford BioTherapeutics; qed therapeutics
Research Funding - 23andMe (Inst); Abbvie (Inst); Astellas Pharma (Inst); Atreca (Inst); Bayer (Inst); boston biomedical (Inst); Bristol-Myers Squibb/Celgene (Inst); Day One Biopharmaceuticals (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); I-MAB (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); pfizer (Inst); PsiOxus Therapeutics (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Totus Medicines (Inst); Tyra Biosciences (Inst)
Other Relationship - AstraZeneca; Karyopharm Therapeutics; novocure; Pancreatic Cancer Action Network
 
Paul Eliezer Oberstein
Consulting or Advisory Role - AstraZeneca; Delcath Systems; Merck; QED Therapeutics; Rubius Therapeutics
Speakers' Bureau - AstraZeneca
Research Funding - Arcus Biosciences (Inst); Merck (Inst); Rafael Pharmaceuticals (Inst); Roche/Genentech (Inst)
Expert Testimony - Ipsen
Travel, Accommodations, Expenses - Merck
 
Anil Nagar
No Relationships to Disclose
 
Shun Yu
No Relationships to Disclose